EUVIMEDEUVIMED entdecken
Crossref

Abstract 5367: Reassessing the Safety of Cilostazol in Heart Failure with Reduced Ejection Fraction: A Propensity-Matched Real-World Analysis

Abstract 5367: Neubewertung der Sicherheit von Cilostazol bei Herzinsuffizienz mit reduzierter Ejektionsfraktion: Propensity-angepasste Real-World-Analyse

George Blankson, Irene Acheampong, Abraham K Carboo, Patrick A Kwaah, Dennis Kumi, Nawal Abdi, Stephen N Djanie, Ikponmwosa Igbinigie, Samuel Sule-Saa, Yagnya Dalal

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.5367 ↗

Auf einen Blick

Bei Erwachsenen mit peripherer arterieller Verschlusskrankheit und HFrEF war Cilostazol im Vergleich zu Pentoxifyllin nicht mit einem erhöhten Arrhythmie- oder Mortalitätsrisiko verbunden.

Fragestellung

Ist Cilostazol bei Patient:innen mit HFrEF und peripherer arterieller Verschlusskrankheit im Vergleich zu Pentoxifyllin mit einem erhöhten Arrhythmie- oder Mortalitätsrisiko verbunden?

Methode

Retrospektive Kohortenstudie in TriNetX; Erwachsene mit peripherer arterieller Verschlusskrankheit und HFrEF; 1:1-Propensity-Score-Matching; Vergleich mit Pentoxifyllin; Follow-up bis 5 Jahre.

Ergebnisse

Nach Matching 1.713 Patient:innen je Gruppe. Für die zusammengesetzte Arrhythmie kein erhöhtes Risiko: 6 Monate HR 0,81 (95 %-KI 0,58–1,13), 1 Jahr 0,88 (0,69–1,12), 3 Jahre 0,92 (0,78–1,09), 5 Jahre 0,95 (0,82–1,10). Mortalität bei 6 Monaten niedriger: HR 0,72 (95 %-KI 0,53–0,98).

Einschränkungen

Beobachtungsdesign; weitere prospektive Studien erforderlich.

Schlussfolgerung der Autor:innen

In dieser großen Real-World-Analyse war Cilostazol bei HFrEF nicht mit erhöhtem arrhythmischem Risiko oder Mortalität gegenüber Pentoxifyllin verbunden.

Kernaussagen

  • 1.713 Patient:innen je Gruppe nach Matching
  • Keine Zunahme der zusammengesetzten Arrhythmie bis 5 Jahre
  • Mortalität nach 6 Monaten niedriger, später kein signifikanter Unterschied

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von George Blankson und 9 weiteren Autor:innen.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cilostazol, a phosphodiesterase-3 inhibitor used for intermittent claudication, is contraindicated in all forms of heart failure due to concerns of increased arrhythmic and mortality risk extrapolated from other inotropic agents. However, direct evidence evaluating its safety in patients with heart failure with reduced ejection fraction (HFrEF) remains limited.

Methods

We conducted a retrospective cohort study using the TriNetX federated electronic health record network, including adults with peripheral artery disease and HFrEF. Patients with HFpEF, LVAD and heart transplant were excluded. Patients receiving cilostazol were compared with those receiving pentoxifylline using 1:1 propensity score matching. Pentoxifylline provides a comparator that treats the same condition without the pro-inotropic, calcium-loading mechanism suspected to drive arrhythmias and mortality in Cilostazol. The primary outcome was composite arrhythmia, defined as atrial fibrillation/flutter, ventricular tachycardia, ventricular fibrillation, or cardiac arrest. Secondary outcomes included individual arrhythmias and all-cause mortality. Outcomes were assessed at 6 months, 1 year, 3 years, and 5 years using Cox proportional hazards models with TrinetX inbuilt analytics.

Results

After matching, 1,713 patients were included in each cohort with well-balanced baseline characteristics (some characteristics are shown in Table 1). Cilostazol was not associated with an increased risk of composite arrhythmia at any time point (6 months: HR 0.81, 95% CI 0.58-1.13; 1 year: HR 0.88, 95% CI 0.69-1.12; 3 years: HR 0.92, 95% CI 0.78-1.09; 5 years: HR 0.95, 95% CI 0.82-1.10). There were no significant differences in atrial fibrillation/flutter, ventricular tachycardia, ventricular fibrillation, or cardiac arrest. All-cause mortality was lower in the cilostazol group at 6 months (HR 0.72, 95% CI 0.53-0.98) but was not significantly different at longer follow-up.

Conclusions

In this large real-world analysis of patients with HFrEF and peripheral artery disease, cilostazol was not associated with increased arrhythmic risk or mortality compared with pentoxifylline. These findings challenge the current class-based contraindication; however, given the observational design, further prospective studies are warranted to better define its safety profile in patients with HFrEF.

Zitieren

APA

Blankson, G., Acheampong, I., Carboo, A. K., Kwaah, P. A., Kumi, D., Abdi, N., Djanie, S. N., Igbinigie, I., Sule-Saa, S., & Dalal, Y. (2026). Abstract 5367: Reassessing the Safety of Cilostazol in Heart Failure with Reduced Ejection Fraction: A Propensity-Matched Real-World Analysis. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.5367

Vancouver

Blankson G, Acheampong I, Carboo AK, Kwaah PA, Kumi D, Abdi N, et al. Abstract 5367: Reassessing the Safety of Cilostazol in Heart Failure with Reduced Ejection Fraction: A Propensity-Matched Real-World Analysis. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.5367

BibTeX
@article{Blankson2026,
  author = {Blankson, George and Acheampong, Irene and Carboo, Abraham K and Kwaah, Patrick A and Kumi, Dennis and Abdi, Nawal and Djanie, Stephen N and Igbinigie, Ikponmwosa and Sule-Saa, Samuel and Dalal, Yagnya},
  title = {Abstract 5367: Reassessing the Safety of Cilostazol in Heart Failure with Reduced Ejection Fraction: A Propensity-Matched Real-World Analysis},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.5367}
}
Kostenlos starten →